EXPEDITED PROCEDURE - EXAMINING GROUP 1642

PATENT S/N 09/096,749

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Shohei Koide icant:

Examiner: L. R. Helms, Ph.D.

09/096,749

Group Art Unit: 1642

June 12, 1998

Docket: 109.034US1

Title:

led:

al No.:

ARTIFICIAL ANTIBODY POLYPEPTIDES

AMENDMENT & RESPONSE UNDER 37 C.F.R. § 1.116

Box AF Commissioner for Patents Washington, D.C. 20231

RECEIVEL S DOUGOO In response to the final Office Action mailed August 15, 2001, please amend the application as follows:

IN THE CLAIMS

Please substitute the claim set in the appendix entitled Clean Version of Pending Claims for the previously pending claim set. The substitute claim set is intended to reflect cancellation of claim 3, and the amendment of previously pending claims 1, 2, 4, and 5. The specific amendments to individual claims are detailed in the following marked up set of claims.

1. [Twice Amended] A fibronectin type III (Fn3) polypeptide monobody comprising at least two Fn3 β-strand domain sequences with a loop region sequence linked between each Fn3 β-strand domain sequence,

wherein [the] at least one monobody loop region sequence varies as compared to the wild-type loop region sequence by deletion of at least two to all amino acids in the loop region sequence, insertion of at least two to 25 amino acids, or replacement of [two to 25] at least two to all the amino acids in [from] the [corresponding] loop region sequence [in wild-type Fn3], and

[wherein the \beta-strand domain of the monobody has at least a 50% total amino acid sequence homology to the corresponding amino acid sequence of wild-type Fn3's βstrand domain sequence]